Prestigious VC

Prestige BioPharma is a Singapore-based biopharmaceutical company specializing in the development of biosimilars and innovative antibody therapeutics. The company's lead program, HD201 (Tuznue), is a biosimilar of trastuzumab (Herceptin) that has completed Phase 3 clinical trials and is under regulatory review in various markets for the treatment of HER2-positive breast and gastric cancers. Its pipeline also includes HD204, a bevacizumab biosimilar in Phase 3, and PBP1510 (ulenistamab), a first-in-class monoclonal antibody targeting PAUF for pancreatic cancer. Prestige BioPharma leverages its proprietary discovery platform to develop high-quality, affordable biologics and novel treatments for oncology and other unmet medical needs. The company is publicly traded on the Korea Exchange and operates research and manufacturing facilities in Singapore and South Korea.